Crestor is unsafe and will be taken off the market.
The consumer group, Public Citizen, is pushing for Crestor (rosuvastatin) to be taken off the market. They say that the rates of kidney damage and rhabdomyolysis are too high.
This is all based on pre-marketing research done by the manufacturer. During these early studies some patients getting Crestor had high protein levels in the urine and 7 patients developed rhabdomyolysis.
But most of these cases occurred with the high 80 mg dose of Crestor. Trials with this dose were stopped...and the 80 mg strength was never marketed.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote